Discovery - University of Dundee - Online Publications

Library & Learning Centre

Phenformin as prophylaxis and therapy in breast cancer xenografts

Standard

Phenformin as prophylaxis and therapy in breast cancer xenografts. / Appleyard, M. V. C. L. (Lead / Corresponding author); Murray, K. E.; Coates, P. J.; Wullschleger, S.; Bray, S. E.; Kernohan, N. M.; Fleming, S.; Alessi, D. R.; Thompson, A. M.

In: British Journal of Cancer, Vol. 106, No. 6, 13.03.2012, p. 1117-1122.

Research output: Contribution to journalArticle

Harvard

Appleyard, MVCL, Murray, KE, Coates, PJ, Wullschleger, S, Bray, SE, Kernohan, NM, Fleming, S, Alessi, DR & Thompson, AM 2012, 'Phenformin as prophylaxis and therapy in breast cancer xenografts' British Journal of Cancer, vol 106, no. 6, pp. 1117-1122., 10.1038/bjc.2012.56

APA

Appleyard, M. V. C. L., Murray, K. E., Coates, P. J., Wullschleger, S., Bray, S. E., Kernohan, N. M., ... Thompson, A. M. (2012). Phenformin as prophylaxis and therapy in breast cancer xenografts. British Journal of Cancer, 106(6), 1117-1122. 10.1038/bjc.2012.56

Vancouver

Appleyard MVCL, Murray KE, Coates PJ, Wullschleger S, Bray SE, Kernohan NM et al. Phenformin as prophylaxis and therapy in breast cancer xenografts. British Journal of Cancer. 2012 Mar 13;106(6):1117-1122. Available from: 10.1038/bjc.2012.56

Author

Appleyard, M. V. C. L. (Lead / Corresponding author); Murray, K. E.; Coates, P. J.; Wullschleger, S.; Bray, S. E.; Kernohan, N. M.; Fleming, S.; Alessi, D. R.; Thompson, A. M. / Phenformin as prophylaxis and therapy in breast cancer xenografts.

In: British Journal of Cancer, Vol. 106, No. 6, 13.03.2012, p. 1117-1122.

Research output: Contribution to journalArticle

Bibtex - Download

@article{66fba5e0f5584d92a608d5529258243d,
title = "Phenformin as prophylaxis and therapy in breast cancer xenografts",
author = "Appleyard, {M. V. C. L.} and Murray, {K. E.} and Coates, {P. J.} and S. Wullschleger and Bray, {S. E.} and Kernohan, {N. M.} and S. Fleming and Alessi, {D. R.} and Thompson, {A. M.}",
year = "2012",
doi = "10.1038/bjc.2012.56",
volume = "106",
number = "6",
pages = "1117--1122",
journal = "British Journal of Cancer",
issn = "0007-0920",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Phenformin as prophylaxis and therapy in breast cancer xenografts

A1 - Appleyard,M. V. C. L.

A1 - Murray,K. E.

A1 - Coates,P. J.

A1 - Wullschleger,S.

A1 - Bray,S. E.

A1 - Kernohan,N. M.

A1 - Fleming,S.

A1 - Alessi,D. R.

A1 - Thompson,A. M.

AU - Appleyard,M. V. C. L.

AU - Murray,K. E.

AU - Coates,P. J.

AU - Wullschleger,S.

AU - Bray,S. E.

AU - Kernohan,N. M.

AU - Fleming,S.

AU - Alessi,D. R.

AU - Thompson,A. M.

PY - 2012/3/13

Y1 - 2012/3/13

N2 - <p>BACKGROUND: Observations that diabetics treated with biguanide drugs have a reduced risk of developing cancer have prompted an enthusiasm for these agents as anti-cancer therapies. We sought to determine the efficacy of the biguanide phenformin in the chemoprophylaxis and in the treatment of oestrogen receptor (ER)-positive MCF7 and receptor triple-negative MDAMB231 xenografts in immunocompromised mice. We also compared the efficacy of phenformin and metformin in the treatment of MDAMB231.</p><p>METHODS: Immunocompromised mice were divided into groups: (1) phenformin administered for 2 weeks prior to cell injection; (2) established tumours treated with phenformin; (3) established tumours treated with metformin (only for MDAMB231 tumours); (4) untreated controls. Post-treatment tumours, liver and spleen were harvested for further analysis.</p><p>RESULTS: Phenformin significantly inhibited both the development and growth of MCF7 and MDAMB231 tumours, and for MDAMB231 at greater efficacy than metformin without murine toxicity. The number of mitotic figures was significantly fewer in xenografts treated with phenformin compared with controls. Results suggested that the mechanism of action of phenformin in vivo is consistent with AMPK activation.</p><p>CONCLUSION: Phenformin has clinical potential as an antineoplastic agent and should be considered for clinical trials both in ER-positive and triple-negative breast cancer. British Journal of Cancer (2012) 106, 1117-1122. doi:10.1038/bjc.2012.56 www.bjcancer.com Published online 23 February 2012 (C) 2012 Cancer Research UK</p>

AB - <p>BACKGROUND: Observations that diabetics treated with biguanide drugs have a reduced risk of developing cancer have prompted an enthusiasm for these agents as anti-cancer therapies. We sought to determine the efficacy of the biguanide phenformin in the chemoprophylaxis and in the treatment of oestrogen receptor (ER)-positive MCF7 and receptor triple-negative MDAMB231 xenografts in immunocompromised mice. We also compared the efficacy of phenformin and metformin in the treatment of MDAMB231.</p><p>METHODS: Immunocompromised mice were divided into groups: (1) phenformin administered for 2 weeks prior to cell injection; (2) established tumours treated with phenformin; (3) established tumours treated with metformin (only for MDAMB231 tumours); (4) untreated controls. Post-treatment tumours, liver and spleen were harvested for further analysis.</p><p>RESULTS: Phenformin significantly inhibited both the development and growth of MCF7 and MDAMB231 tumours, and for MDAMB231 at greater efficacy than metformin without murine toxicity. The number of mitotic figures was significantly fewer in xenografts treated with phenformin compared with controls. Results suggested that the mechanism of action of phenformin in vivo is consistent with AMPK activation.</p><p>CONCLUSION: Phenformin has clinical potential as an antineoplastic agent and should be considered for clinical trials both in ER-positive and triple-negative breast cancer. British Journal of Cancer (2012) 106, 1117-1122. doi:10.1038/bjc.2012.56 www.bjcancer.com Published online 23 February 2012 (C) 2012 Cancer Research UK</p>

UR - http://www.scopus.com/inward/record.url?scp=84858287883&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.56

DO - 10.1038/bjc.2012.56

M1 - Article

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

VL - 106

SP - 1117

EP - 1122

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy